Pharmacogenetic Evidence That Cd36Is a Key Determinant of the Metabolic Effects of Pioglitazone
Open Access
- 1 December 2002
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 277 (50), 48501-48507
- https://doi.org/10.1074/jbc.m206655200
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- The Mechanisms of Action of PPARsAnnual Review of Medicine, 2002
- Defective Fatty Acid Uptake in the Spontaneously Hypertensive Rat Is a Primary Determinant of Altered Glucose Metabolism, Hyperinsulinemia, and Myocardial HypertrophyPublished by Elsevier ,2001
- Comprehensive Messenger Ribonucleic Acid Profiling Reveals That Peroxisome Proliferator-Activated Receptor Activation Has Coordinate Effects on Gene Expression in Multiple Insulin-Sensitive TissuesEndocrinology, 2001
- Peroxisome Proliferator-Activated Receptors: From Genes to PhysiologyPublished by The Endocrine Society ,2001
- Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinedionesJournal of Clinical Investigation, 2000
- Genetics of Cd36 and the clustering of multiple cardiovascular risk factors in spontaneous hypertensionJournal of Clinical Investigation, 1999
- PPARγ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytesAtherosclerosis, 1998
- PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDLCell, 1998
- Troglitazone action is independent of adipose tissue.Journal of Clinical Investigation, 1997
- Disordered metabolism in diabetes: Have we underemphasized the fat component?Journal of Cellular Biochemistry, 1994